KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

(4:20)

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

(5:1econd)

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

(3:9)

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12

(18:38)

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

(9:2)

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)

(4:50)

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

(53)

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

(1:43)

KEYNOTE-522: optimal preoperative IO and residual disease management in TNBC

(1:56)

KEYTRUDA Phase 3 KEYNOTE-522 Trial Data

(8:45)

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

(4:20)

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

(1:3)

Highlights in breast cancer at ESMO 2024: KEYNOTE-522

(32)

SABCS Snippets: KEYNOTE-522 Phase 3 Results

(11:45)

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

(4:54)

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY \u0026 more

(2:53)

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS

(3:34)

The case for neoadjuvant pembrolizumab in TNBC

(1:42)

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBC

(1:46)